@article{MateosDimopoulosCavoetal.2021,
  author    = {Mateos, Maria-Victoria and Dimopoulos, Meletios A. and Cavo, Michele and Suzuki, Kenshi and Knop, Stefan and Doyen, Chantal and Lucio, Paulo and Nagy, Zsolt and Pour, Ludek and Grosicki, Sebastian and Crepaldi, Andre and Liberati, Anna Marina and Campbell, Philip and Yoon, Sung-Soo and Iosava, Genadi and Fujisaki, Tomoaki and Garg, Mamta and Iida, Shinsuke and Blad{\´e}, Joan and Ukropec, Jon and Pei, Huiling and Van Rampelbergh, Rian and Kudva, Anupa and Qi, Ming and San-Miguel, Jesus},
  title     = {Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE},
  series = {Clinical Lymphoma, Myeloma \& Leukemia},
  volume    = {21},
  journal   = {Clinical Lymphoma, Myeloma \& Leukemia},
  doi       = {10.1016/j.clml.2021.06.005},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370456},
  pages     = {785-798},
  year      = {2021},
  abstract  = {Background In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved progression-free survival (PFS) and overall survival (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. We present a subgroup analysis of ALCYONE by patient frailty status. Patients and Methods Frailty assessment was performed retrospectively using age, Charlson comorbidity index, and baseline Eastern Cooperative Oncology Group performance status score. Patients were classified as fit (0), intermediate (1), or frail (≥2); a nonfrail category combined fit and intermediate patients. Results Among randomized patients (D-VMP, n = 350; VMP, n = 356), 391 (55.4\%) were nonfrail (D-VMP, 187 [53.4\%]; VMP, 204 [57.3\%]) and 315 (44.6\%) were frail (163 [46.6\%]; 152 [42.7\%]). After 40.1-months median follow-up, nonfrail patients had longer PFS and OS than frail patients, but benefits of D-VMP versus VMP were maintained across subgroups: PFS nonfrail (median, 45.7 vs. 19.1 months; hazard ratio [HR], 0.36; P < .0001), frail (32.9 vs. 19.5 months; HR, 0.51; P < .0001); OS nonfrail (36-month rate, 83.6\% vs. 74.5\%), frail (71.4\% vs. 59.0\%). Improved greater than or equal to complete response and minimal residual disease (10-5)-negativity rates were observed for D-VMP versus VMP across subgroups. The 2 most common grade 3/4 treatment-emergent adverse events were neutropenia (nonfrail: 39.2\% [D-VMP] and 42.4\% [VMP]; frail: 41.3\% and 34.4\%) and thrombocytopenia (nonfrail: 32.8\% and 36.9\%; frail: 36.9\% and 39.1\%). Conclusion Our findings support the clinical benefit of D-VMP in transplant-ineligible NDMM patients enrolled in ALCYONE, regardless of frailty status.},
  language  = {en}
}
@article{SteinhardtZhouKrummenastetal.2020,
  author    = {Steinhardt, Maximilian Johannes and Zhou, Xiang and Krummenast, Franziska and Meckel, Katharina and Nickel, Katharina and B{\"o}ckle, David and Messerschmidt, Janin and Knorz, Sebastian and Dierks, Alexander and Heidemeier, Anke and Lapa, Constantin and Einsele, Hermann and Rasche, Leo and Kort{\"u}m, Klaus Martin},
  title     = {Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma},
  series = {International Journal of Immunopathology and Pharmacology},
  volume    = {34},
  journal   = {International Journal of Immunopathology and Pharmacology},
  doi       = {10.1177/2058738420980258},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236235},
  pages     = {1-5},
  year      = {2020},
  abstract  = {We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab ("Pom-PAD-Dara"), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.},
  language  = {en}
}